OBJECTIVE: To analyze the profile of the HLA-B27 and B7 cross-reactive group (CREG) alleles and the role of these markers in disease characterization and progression in patients with undifferentiated spondyloarthropathies (uSpA). METHODS: A total of 80 patients with a diagnosis of uSpA (40 HLA-B27 positive and 40 HLA-B27 negative) were prospectively studied for 2 years. The control group consisted of 66 HLA-B27 positive and 112 HLA-B27 negative individuals without a history of seronegative SpA. HLA-B alleles were typed at low (B7-CREG alleles, i.e., B*7, B*54, B*55, B*56, B*40, B*42) or high resolution (B*27 alleles) using polymerase chain reaction-amplified DNA hybridized with sequence-specific oligonucleotide probes. RESULTS: HLA-B*2705 was the most frequent allele, observed in 92.5% of the patients and in 77% of the controls, followed by the HLA-B*2702, observed in 5% of the patients and in 12% of the controls. HLA-B*2704 was observed in only one patient (2.5%), and was absent in the control population. HLA-B*2703 (6%) and HLA-B*2707 (5%) alleles were observed only in controls. No associations between HLA-B*27 alleles or B7-CREG alleles and any specific manifestation of uSpA were observed. HLA-B27 positive patients more frequently presented juvenile onset SpA (p = 0.002) and progression to ankylosing spondylitis (AS) (p = 0.03) than did HLA-B27 negative patients. The B7-CREG alleles were observed in 5% of the HLA-B27 positive uSpA group, in 25% of the HLA-B27 negative uSpA group, in 7% of the HLA-B27 positive controls, and in 13% of the HLA-B27 negative controls; a significant association was observed between the presence of the B7-CREG and the HLA-B27 negative uSpA group (p = 0.012). CONCLUSION: The frequency of the HLA-B*2705 allele among the B27 positive uSpA patients of this series was closely similar to that reported for patients with ankylosing spondylitis (AS). The presence of HLA-B*27 alleles was associated with the progression to AS, and the presence of B7-CREG was associated with uSpA in the HLA-B27 negative group.
OBJECTIVE: To analyze the profile of the HLA-B27 and B7 cross-reactive group (CREG) alleles and the role of these markers in disease characterization and progression in patients with undifferentiated spondyloarthropathies (uSpA). METHODS: A total of 80 patients with a diagnosis of uSpA (40 HLA-B27 positive and 40 HLA-B27 negative) were prospectively studied for 2 years. The control group consisted of 66 HLA-B27 positive and 112 HLA-B27 negative individuals without a history of seronegative SpA. HLA-B alleles were typed at low (B7-CREG alleles, i.e., B*7, B*54, B*55, B*56, B*40, B*42) or high resolution (B*27 alleles) using polymerase chain reaction-amplified DNA hybridized with sequence-specific oligonucleotide probes. RESULTS:HLA-B*2705 was the most frequent allele, observed in 92.5% of the patients and in 77% of the controls, followed by the HLA-B*2702, observed in 5% of the patients and in 12% of the controls. HLA-B*2704 was observed in only one patient (2.5%), and was absent in the control population. HLA-B*2703 (6%) and HLA-B*2707 (5%) alleles were observed only in controls. No associations between HLA-B*27 alleles or B7-CREG alleles and any specific manifestation of uSpA were observed. HLA-B27 positive patients more frequently presented juvenile onset SpA (p = 0.002) and progression to ankylosing spondylitis (AS) (p = 0.03) than did HLA-B27 negative patients. The B7-CREG alleles were observed in 5% of the HLA-B27 positive uSpA group, in 25% of the HLA-B27 negative uSpA group, in 7% of the HLA-B27 positive controls, and in 13% of the HLA-B27 negative controls; a significant association was observed between the presence of the B7-CREG and the HLA-B27 negative uSpA group (p = 0.012). CONCLUSION: The frequency of the HLA-B*2705 allele among the B27 positive uSpApatients of this series was closely similar to that reported for patients with ankylosing spondylitis (AS). The presence of HLA-B*27 alleles was associated with the progression to AS, and the presence of B7-CREG was associated with uSpA in the HLA-B27 negative group.
Authors: Percival D Sampaio-Barros; Elza Maria F P Cerqueira; Sílvio M Rezende; Lucimara Maeda; Roseneide A Conde; Verônica A Zanardi; Manoel Barros Bértolo; José Ribeiro de Menezes Neto; Adil M Samara Journal: Clin Rheumatol Date: 2006-03-30 Impact factor: 2.980
Authors: Percival D Sampaio-Barros; Roseneide A Conde; Eduardo A Donadi; Rubens Bonfiglioli; Lilian T L Costallat; Adil M Samara; Manoel B Bértolo Journal: Rheumatol Int Date: 2007-08-24 Impact factor: 2.631
Authors: Rubens Bonfiglioli; Roseneide A Conde; Percival D Sampaio-Barros; Paulo Louzada-Junior; Eduardo A Donadi; Manoel B Bertolo Journal: Clin Rheumatol Date: 2007-11-03 Impact factor: 2.980
Authors: Maxime Dougados; Alexandre Sepriano; Anna Molto; Miranda van Lunteren; Sofia Ramiro; Manouk de Hooge; Rosaline van den Berg; Victoria Navarro Compan; Christophe Demattei; Robert Landewé; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2017-07-06 Impact factor: 19.103
Authors: Cristina Fernández-Carballido; Carolina Tornero; M Carmen Castro-Villegas; Eva Galindez; José Francisco García-Llorente; María Luz García-Vivar; Beatriz Joven-Ibáñez; Xavier Juanola; Claudia Urrego-Laurín; Clementina López-Medina; Raquel Almodovar; Nieves Martínez-Alberola; Teresa Ruiz-Jimeno; Eugenio de Miguel Journal: RMD Open Date: 2020-09
Authors: Lovro Lamot; Fran Borovecki; Lana Tambic Bukovac; Mandica Vidovic; Marija Perica; Kristina Gotovac; Miroslav Harjacek Journal: PLoS One Date: 2014-12-15 Impact factor: 3.240